Skip to main content
. Author manuscript; available in PMC: 2014 Dec 28.
Published in final edited form as: J Control Release. 2013 Oct 2;172(3):1045–1064. doi: 10.1016/j.jconrel.2013.09.026

Fig. 2.

Fig. 2

Pegylated liposomal doxorubicin (Doxil® / Caelyx®), Particle size is 80–90 nm. Developed by Johnson and Johnson and approved in 1995 for treating AIDS-related Kaposi's sarcoma. So far, the indications have been extended to ovarian cancer and multiple myeloma. Illustration modified from FDA label.